Saatja: "Tuberculosis" <
[email protected]>
Saaja: "Költringer Fiona" <
[email protected]>, "Indra Alexander" <
[email protected]>, "Vinciane SIZAIRE" <
[email protected]>, "Wouter Arrazola de Oñate" <
[email protected]>, "Yuliana Atanasova" <
[email protected]>, "zvjezdana.lovric" <
[email protected]>, "goranka.petrovic" <
[email protected]>, "Costas Constantinou" <
[email protected]>, "Anna Papandreou" <
[email protected]>, "Věra Dvořáková" <
[email protected]>, "Jiří Wallenfels" <
[email protected]>, "Anders Koch" <
[email protected]>, "Troels Lillebæk" <
[email protected]>, "Kersti Villand" <
[email protected]>, "Piret Viiklepp" <
[email protected]>, "Silja Mentula" <
[email protected]>, "Hanna Soini" <
[email protected]>, "Delphine Viriot" <
[email protected]>, "Jean-Paul GUTHMANN" <
[email protected]>, "KroegerS" <
[email protected]>, "haasw" <
[email protected]>, "s.chatzianastasiou" <
[email protected]>, "bakosagi" <
[email protected]>, "Kamilla Sigríður Jósefsdóttir - Landl" <
[email protected]>, "Sarah Jackson" <
[email protected]>, "Phil Downes" <
[email protected]>, "Mary O' Meara" <
[email protected]>, "Cirillo Daniela" <
[email protected]>, "Sane Schepisi Monica" <
[email protected]>, "Ieva Rimšāne" <
[email protected]>, "Visscher Carla" <
[email protected]>, "Walser-Domjan Esther" <
[email protected]>, "Alvyda Naujokaitė" <
[email protected]>, "Jurgita Pakalniškienė" <
[email protected]>,
[email protected], "Anne Vergison" <
[email protected]>, "Melillo Tanya at Health Regulation" <
[email protected]>, "Attard Antoinette 1 at Health Regulation" <
[email protected]>, "Geraldine Ter Linde" <
[email protected]>, "Richard Anthony" <
[email protected]>, "Karine Nordstrand" <
[email protected]>, "Anne Torunn Mengshoel" <
[email protected]>, "s.wesolowski" <
[email protected]>, "Maria Korzeniewska-Koseła" <
[email protected]>, "afssmd" <
[email protected]>, "Maria Isabel Carvalho" <
[email protected]>, "Nicoleta Cioran" <
[email protected]>,
[email protected], "Ivan Solovič" <
[email protected]>, "Sanja Grm Zupan" <
[email protected]>, "petra.svetina" <
[email protected]>, "Christine Schwarz" <
[email protected]>, "Zaida Herrador Ortiz" <
[email protected]>, "Petra Edquist" <
[email protected]>, "Maria Axelsson" <
[email protected]>
Teema: RE: Nomination of national respondents for TB Monitoring in the EU/EEA (2025 data collection)
Kuupäev: 2025-03-18 11:08
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.
Dear National Focal Points for Tuberculosis,
To further inform your decision-making process in relation to the
nominations for the TB monitoring data collection, please consider the
following clarifications:
* During the data collection, we will kindly request a single, coordinated
national response from each EU/EEA country.
* We encourage collective work in responding the online questionnaire. To
facilitate the submission process, TB NFPs can delegate the task of replying
to the questionnaire among several people (i.e. the national nominees).
Thus, we will need to grant these experts access to REDCap and therefore the
nomination process we have just initiated.
* At least one person should be nominated. If you would like to nominate
more than 10 respondents, please contact us via email.
* The group of experts could include both general experts as well as
specialists, covering the areas of TB policy and implementation, TB
programme and planning, TB prevention, TB diagnosis, TB treatment and care,
community engagement and people-centred care. It is important to keep in
mind is that all responses should reflect the country-level situation.
* Please see below a general description of the topics included in the TB
monitoring questionnaire that will be released in April, to inform your
decision on whom to involve at national level. Please note that most of the
questions are single/multiple choice. There is always an open question at
the end of each section to provide clarifications or further information. We
will also request links to national documents or (clinical) guidance
documents.
Areas
Topics included
Example of questions to be asked
Enabling environment
* Availability of National Strategic Plan (NSP) and its alignment with the
Regional TB Action Plan
* Protection against stigma and discrimination
* Social protection and collaboration with other services
* Availability of TB research agenda
* Risk group prioritization
* Access to TB services for migrants
* Does your county have a national strategy, plan or policy for prevention
and control of TB?
* Does your country have a national policy to specifically provide social
protection services to TB-affected individuals (e.g., socio- economic or
nutritional support)?
* Does your country allocate separate budget for the management of TB among
migrants?
Prevention
* Availability of TB infection (TBI) testing and costs to the individual
* TB Preventive treatment (TPT) practices
* Availability of TPT regimens
* Availability of counseling
* TPT coverage
* Does your county offer testing for TBI? If yes, what are the costs for
individuals undergoing testing for TBI?
* Is free-of-charge testing for TBI available in your country for people who
ae not covered by health insurance?
* Which TPT regimens are available in your country?
* Which constraints, if any, are limiting or preventing the scale-up of TPT
in your country?
Testing and diagnosis
* Availability of policy guidance on TB screening and its specifics
* TB screening and testing practices and settings, costs to the individual
* Outreach to migrant populations
* Availability of policy guidance on TB diagnosis and its specifics
* Drug-resistance testing policies and practices
* Diagnostic tools used
* Does your country conduct systematic screening for TB disease among
certain groups?
* Please specify the groups who benefit from free-of-charge screening and
testing for TB disease.
* Which diagnostic tools are used as the initial diagnostic test for TB
disease in your country?
* What is the average time from a person’s initial contact with the health
system after showing TB symptoms to the commencement of TB treatment in your
country?
Treatment and care
* Availability of policy guidance for drug-susceptible and drug-resistant TB
and its specifics
* Access to novel shorter treatment regimens
* Availability of people-centered treatment options and other treatment
adherence interventions
* Approaches to hospitalization
* Cost to individual to undergo treatment
* Access to treatment for people without health insurance
* Alignment of treatment guidelines in prisons
* Does your country have national treatment guidelines for drug-susceptible
TB?
* Does your country have national treatment guidelines for drug-resistant
TB?
* Which treatment options for drug-susceptible and drug-resistant TB are
available in your country?
* According to your national policies/guidelines, is hospitalization
required for all people initiating TB treatment?
* Does your country’s policy permit the concomitant treatment of
multidrug-resistant TB and viral hepatitis C in people with co-infection?
Impact
* TB incidence
* TB mortality
* Care for migrants with TB
* These data will be retrieved from TESSy
Please use the following link to submit your nominations:
https://ec.europa.eu/eusurvey/runner/TBmonitoringnominations
We would be grateful for to receive your replies latest by 26 March 2025.
Please do not hesitate to contact me if you have any questions.
Best regards,
Senia Rosales-Klintz, on behalf of the ECDC TB team.
European Centre for Disease Prevention and Control (ECDC)Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00
<https://www.ecdc.europa.eu/> www.ecdc.europa.eu
Follow ECDC on:
<http://www.facebook.com/ECDC.EU>
<https://bsky.app/profile/ecdc.europa.eu>
<http://www.linkedin.com/company/ecdc>
<http://www.youtube.com/user/ECDCchannel>
<https://www.instagram.com/ecdc.eu>
<https://www.threads.net/@ecdc.eu>
Classified as ECDC NORMAL
From: Tuberculosis <
[email protected]>
Sent: 17 March 2025 18:04
To: Költringer Fiona <
[email protected]>; Indra Alexander
<
[email protected]>; Vinciane SIZAIRE <
[email protected]>;
Wouter Arrazola de Oñate <
[email protected]>; Yuliana Atanasova
<
[email protected]>; zvjezdana.lovric <
[email protected]>;
goranka.petrovic <
[email protected]>; Costas Constantinou
<
[email protected]>; Anna Papandreou
<
[email protected]>; Věra Dvořáková <
[email protected]>; Jiří
Wallenfels <
[email protected]>; Anders Koch <
[email protected]>; Troels Lillebæk
<
[email protected]>; Kersti Villand <
[email protected]>; Piret Viiklepp
<
[email protected]>; Silja Mentula <
[email protected]>; Hanna Soini
<
[email protected]>; Delphine Viriot
<
[email protected]>; Jean-Paul GUTHMANN
<
[email protected]>; KroegerS <
[email protected]>;
haasw <
[email protected]>; s.chatzianastasiou <
[email protected]>;
bakosagi <
[email protected]>; Kamilla Sigríður Jósefsdóttir - Landl
<
[email protected]>; Sarah Jackson <
[email protected]>; Phil Downes
<
[email protected]>; Mary O' Meara <
[email protected]>; Cirillo Daniela
<
[email protected]>; Sane Schepisi Monica <
[email protected]>;
Ieva Rimšāne <
[email protected]>; Visscher Carla
<
[email protected]>; Walser-Domjan Esther <
[email protected]>;
Alvyda Naujokaitė <
[email protected]>; Jurgita Pakalniškienė
<
[email protected]>;
[email protected]; Anne Vergison
<
[email protected]>; Melillo Tanya at Health Regulation
<
[email protected]>; Attard Antoinette 1 at Health Regulation
<
[email protected]>; Geraldine Ter Linde
<
[email protected]>; Richard Anthony <
[email protected]>;
Karine Nordstrand <
[email protected]>; Anne Torunn Mengshoel
<
[email protected]>; s.wesolowski <
[email protected]>;
Maria Korzeniewska-Koseła <
[email protected]>; afssmd
<
[email protected]>; Maria Isabel Carvalho <
[email protected]>;
Nicoleta Cioran <
[email protected]>;
[email protected]; Ivan
Solovič <
[email protected]>; Sanja Grm Zupan
<
[email protected]>; petra.svetina
<
[email protected]>; Christine Schwarz
<
[email protected]>; Zaida Herrador Ortiz <
[email protected]>; Petra
Edquist <
[email protected]>; Maria Axelsson
<
[email protected]>
Cc: NC_CCB_Austria <
[email protected]>; sigrid.kiermayr
<
[email protected]>; koen.blot
<
[email protected]>;
[email protected]; Julien Sohier
<
[email protected]>; Zhivka Getsova <
[email protected]>; Iva
Christova <
[email protected]>; kcapak <
[email protected]>; bernard.kaic
<
[email protected]>; Elisavet Constantinou <
[email protected]>;
Czech Republic Generic Email Box - <
[email protected]>; Hana Orlíková
<
[email protected]>; Kamilla Grønborg Laut <
[email protected]>; Stine Ulendorf
Jacobsen <
[email protected]>; Kärt Sõber <
[email protected]>; Julia Geller
<
[email protected]>; Estonia Generic Email Box -
<
[email protected]>; Otto Helve <
[email protected]>; Savolainen-Kopra
Carita <
[email protected]>; Paula GARCIA-LOBATO
<
[email protected]>; Anne-Catherine VISO
<
[email protected]>; Rathmachers, Lea
<
[email protected]>; Germany Generic Email Box - <
[email protected]>; Rexroth,
Ute <
[email protected]>; Theodora Kalomama <
[email protected]>; Dimitrios
Paraskevis <
[email protected]>; Christakis Chatzichristodoulou
<
[email protected]>; Dr. Dánielisz Ágnes
<
[email protected]>; Cecília Müller <
[email protected]>;
[email protected]; Guðrún Aspelund - Landl
<
[email protected]>; Lois O'Connor <
[email protected]>; Aine
Grace <
[email protected]>; Patricia Garvey <
[email protected]>;
Louise Cullen <
[email protected]>; Lisa Domegan <
[email protected]>;
Maraglino Francesco Paolo <
[email protected]>; Antra Bormane
<
[email protected]>; Dehler Silvia, Dr. med. <
[email protected]>;
Nerija Kuprevičienė <
[email protected]>; Jurgita Pakalniškienė
<
[email protected]>; Jean-Claude Schmit
<
[email protected]>; Gauci Charmaine at Health Regulation
<
[email protected]>; Hester de Melker <
[email protected]>; Susan
van den Hof <
[email protected]>; Macdonald, Emily Ann
<
[email protected]>; Heidi Lange <
[email protected]>; Zacharczuk
Katarzyna <
[email protected]>; Mariana Ferreira
<
[email protected]>; Pedro Licinio Pinto Leite
<
[email protected]>;
[email protected]; André Peralta Santos
<
[email protected]>; Adriana Pistol <
[email protected]>;
lucia.paulikova <
[email protected]>; ecdc <
[email protected]>; maja.socan
<
[email protected]>; Slovenia Generic Email Box - <
[email protected]>;
Sierra Moros. María José <
[email protected]>; Simón Soria. Fernando
<
[email protected]>; Sweden Generic Email Box -
<
[email protected]>; Sweden Generic Email Support -
<
[email protected]>; Agneta Falk Filipsson
<
[email protected]>; Sara Bengtsson
<
[email protected]>; birgitta.lesko
<
[email protected]>; anette.richardson
<
[email protected]>; Country Cooperation
<
[email protected]>; Senia Rosales-Klintz
<
[email protected]>; Tuberculosis
<
[email protected]>; ECDC Info <
[email protected]>
Subject: Nomination of national respondents for TB Monitoring in the EU/EEA
(2025 data collection)
Importance: High
To: National Focal Points for Tuberculosis
CC: National Coordinators, ECDC Country Cooperation
Dear National Focal Points for Tuberculosis,
As part of our ongoing efforts to prevent and control tuberculosis (TB)
within the EU/EEA, the European Centre for Disease Prevention and Control
(ECDC) is enhancing its monitoring system for TB in the context of
Sustainable Development Goals (SDGs). The enhanced TB monitoring system is
designed to complement existing surveillance data with contextual policy and
practice information. The findings will help identify gaps in the TB
response that need acceleration to achieve the incidence and mortality
reduction targets set by the SDGs.
Data collection will be conducted by an ECDC supplier - the Centre of
Excellence for Health, Immunity, and Infections (CHIP) at Rigshospitalet in
Copenhagen, Denmark. In October 2023, ECDC selected CHIP to assist in
monitoring progress towards the SDGs related to HIV, viral hepatitis,
sexually transmitted infections (STIs), and TB. This project aims to ensure
alignment across disease areas and produce both disease-specific and
cross-disease outputs. The data collected within the TB monitoring will be
supplemented with surveillance information provided by countries through the
European Surveillance System (TESSy).
We are writing to request the nomination of national experts that will the
respondents from your country the upcoming data collection on TB monitoring.
The success of this monitoring effort relies heavily on the engagement of a
diverse range of stakeholders. Hence, we suggest the involvement of TB
programme managers, clinicians, drug procurement specialists,
microbiologists, civil society and NGO representatives in discussion and
completion of the monitoring questionnaire. Their collective expertise is
crucial for the comprehensive response to the monitoring questions, which
focuses on policies and practices related to: TB prevention, TB testing and
diagnosis, TB treatment, and enabling environment for TB management.
The data collection will be done the REDCap platform during April-May 2025.
At least one person from each country should be registered in REDCap to
complete the questionnaire, although multiple individuals can have access.
One designated person will be responsible for verifying the data.
Please use the following link to submit your nominations:
https://ec.europa.eu/eusurvey/runner/TBmonitoringnominations
We would be grateful for to receive your replies latest by 26 March 2025.
After the nomination of national experts is completed, we will reach out to
them directly with the request to sign ECDC Terms of Use for REDCap and
process their registration at the platform.
Please do not hesitate to contact me if you have any questions or if you
require more time to complete the nomination process.
Thank you for your cooperation and commitment to improving TB control in the
EU/EEA.
Best regards,
Senia Rosales-Klintz, on behalf of the ECDC TB team.
European Centre for Disease Prevention and Control (ECDC)Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00
<https://www.ecdc.europa.eu/> www.ecdc.europa.eu
Follow ECDC on:
<http://www.facebook.com/ECDC.EU>
<https://bsky.app/profile/ecdc.europa.eu>
<http://www.linkedin.com/company/ecdc>
<http://www.youtube.com/user/ECDCchannel>
<https://www.instagram.com/ecdc.eu>
<https://www.threads.net/@ecdc.eu>
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly
requested, to, consecutively, refrain from disclosing its content to any
third party, delete it and inform its sender of the erroneous transmittal.